PDF / 27 KB 
collectBayerNews_20090701_0315_en.pdf BayerNews_20090701_0315_en.pdf
Leverkusen, July 1, 2009 - Bayer Schering Pharma AG, Germany and Bayer
HealthCare Pharmaceuticals Inc. together with Schering Corporation have filed a
patent infringement lawsuit in the U.S. Federal Court in the District of
Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical
Industries, Ltd.. The lawsuit concerns Teva's application to the FDA for
approval to market a generic form of Levitra®, Bayer Schering Pharma's therapy
for the treatment of erectile dysfunction, prior to patent expiration. The
patent at issue in the suit is Bayer Schering Pharma's U.S. Patent No.
6,362,178, expiring in 2018. In the US, Levitra® is marketed by Schering-Plough
and GlaxoSmithKline.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Bayer Schering
Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, General Medicine, Specialty Medicine and Women's
Healthcare. With innovative products, Bayer Schering Pharma aims for leading
positions in specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives to improve
the quality of life. Find more information at www.bayerscheringpharma.de.
